Date: June 19, 2026 | 03:00 PM - 4:30 PM (IST)
The global clinical trials market is estimated at over $80–90 billion in 2024 and is projected to surpass $120 billion by 2030, driven by rising R&D investments, the growth of biologics and precision medicine, and increasing trial complexity. The Asia-Pacific region is emerging as the fastest-growing market, as sponsors shift studies to geographies offering faster patient recruitment, cost efficiencies, and diverse populations.
India is rapidly emerging as a premier hub for global clinical research, driven by its massive, diverse patient population and a cost advantage of 30–50% compared to Western markets.
The country is establishing a network of over 1,000 accredited clinical trial sites to strengthen domestic biopharma manufacturing, accelerate drug development, and upgrade research infrastructure, as part of the Rs 10,000 crore Biopharma SHAKTI initiative.
Enhanced by ongoing regulatory reforms, the nation’s clinical trials sector, valued at approximately $1.4 billion in 2024, is on a strong growth trajectory, projected to exceed $2.2 billion by 2030. Currently hosting 3–5% of global trials, India is well-positioned to expand its footprint as infrastructure and regulatory processes continue to improve.
The sector is boosted by digital trials, decentralized models, faster approvals, and government support. Yet, challenges persist regarding regulatory hurdles, site capabilities, patient awareness, and intense competition within the Asia-Pacific region.
This webinar will explore whether India can truly emerge as a global clinical trials hub by analysing current market dynamics, benchmarking against global trends, and identifying actionable strategies to enhance competitiveness and accelerate growth.
Key discussion points:
•India’s current position in the global clinical trials market
•Trial execution with data integrity and global compliance standards
•Strengthening infrastructure, investigator capability, and digital maturity
•Readiness for hybrid, tech-enabled, and remote trial models
•Enhancing patient protection, transparency, and public perception
•Government support and public-private collaboration
•Can India emerge as a preferred global clinical trial hub?
Entry to the e-conference is extended only to professionals based on merit, please submit your registration form to apply for complimentary registration.
